Roche boosts digital health stable with MySugr buy

Roche HQ
MySugr's apps will be an "integral part" of Roche's digital health services in diabetes care.

Roche has acquired MySugr, a privately held digital diabetes management player, for an undisclosed sum. MySugr’s apps will become a “focal part” of Roche’s strategy for integrated diabetes management.

Founded in 2012, in Vienna, MySugr focuses on app-based care for people with diabetes. Its offerings include the eponymous MySugr app, which automatically syncs data from a range of diabetes devices and provides feedback and motivation to help people manage their disease. It is available in 52 countries and 13 languages.

A user may purchase a “pro” version of the app with additional functions, such as bolus calculation and access to a certified diabetes educator, who gives personalized advice based on the individual’s diabetes data.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The company also offers some web apps and a pair of iOS apps, including a “scanner” app that allows users to transfer data from their blood glucose meter to the mySugr app by taking a picture of the meter’s screen.

We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life,” said Roche Diabetes Care CEO Roland Diggelmann, in a statement.

MySugr counts Roche Venture Fund and iSeed Ventures among its investors.

The deal comes 4 months after reports emerged that the Swiss pharma was “considering options” for its diabetes care business, including a spinoff or a sale. At the time, Diggelmann put the rumors to rest, saying Roche was on the hunt for deals to prop up diabetes care, the sales of which sank 4% in fiscal 2016 thanks to pricing pressure in the U.S.

Read more on

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.